An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-000172-16

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to demonstrate that the combination of rituximab and chlorambucil is safe by examining the adverse event profile.


Critère d'inclusion

  • CD20-positive B-cell chronic lymphocytic leukemia

Liens